GlobeNewsWire · GTLL · October 26, 2026

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

Get the app for more

Explore stock news, insights and company research.